AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23993247 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 73
Study 23993247 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 73
Study 21936938 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy protein supplement (HEPS)
Number of subjects: 200
Study 21936938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study 19015627 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 0
Study 19015627 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 0
Study 19015627 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 0
Study 15164887 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (0.3 mg per kg per hour)
Number of subjects: 16
Study 15164887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11393351 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 332
Study 11393351 — intervention group
Group type: COMPARATOR
Intervention: Macrolides (azithromycin, clarithromycin, roxithromycin)
Number of subjects: 332
Study 9581739 — intervention group
Group type: COMPARATOR
Intervention: Single-coil configuration
Number of subjects: 50
Study 9581739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-coil configuration
Number of subjects: 50
Study 9419761 — intervention group
Group type: EXPERIMENTAL
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 42
Study 9419761 — intervention group
Group type: COMPARATOR
Intervention: Amniocentesis
Number of subjects: 42
Study 9419761 — intervention group
Group type: COMPARATOR
Intervention: Control group (venipuncture)
Number of subjects: 42
Study 2927460 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (15 micrograms per kilogram of body weight)
Number of subjects: 10
Study 2927460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2927460 — intervention group
Group type: COMPARATOR
Intervention: Comparison group of 10 non-smokers
Number of subjects: 10
Study 14673617 — intervention group
Group type: EXPERIMENTAL
Intervention: GaAs laser treatment applied over three trigger points bilaterally and one point in the taut bands in trapezius muscle bilaterally with a frequency of 1000 Hz for 2 min over each point once a day for 10 days during a period of 2 weeks
Number of subjects: 53
Study 14673617 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (laser instrument switched off) with the same treatment protocol
Number of subjects: 53
Study 31048013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (4 mg/kg/d)
Number of subjects: 32
Study 31048013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28507108 — intervention group
Group type: EXPERIMENTAL
Intervention: ABX464 (up to 150 mg once a day)
Number of subjects: 66
Study 28507108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26644127 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint‐induced movement therapy (CIMT) combined with motor and sensory‐motor interventions
Number of subjects: 216
Study 26644127 — intervention group
Group type: COMPARATOR
Intervention: Standard of care occupational and physical therapy
Number of subjects: 216
Study 23547654 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred care pathway developed for transition from hospital to follow-up in primary care.
Number of subjects: 3
Study 23547654 — intervention group
Group type: COMPARATOR
Intervention: Disease-based care pathways used within hospitals.
Number of subjects: 3
Study 21748303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread fortified with ferrous sulfate (labeled with (59)Fe as sulfate)
Number of subjects: 50
Study 21748303 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread fortified with ferrous fumarate (labeled with (55)Fe as fumarate)
Number of subjects: 50
Study 21748303 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects consuming bread fortified with ferrous sulfate
Number of subjects: 50
Study 21748303 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive subjects consuming bread fortified with ferrous sulfate
Number of subjects: 50
Study 21748303 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects consuming bread fortified with ferrous fumarate
Number of subjects: 50
Study 21748303 — intervention group
Group type: COMPARATOR
Intervention: H. pylori-positive subjects consuming bread fortified with ferrous fumarate
Number of subjects: 50
Study 21748303 — intervention group
Group type: EXPERIMENTAL
Intervention: After administration of a proton pump inhibitor
Number of subjects: 50
Study 19922603 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural exercise therapy
Number of subjects: 88
Study 19922603 — intervention group
Group type: COMPARATOR
Intervention: Regular physiotherapy
Number of subjects: 88
Study 16508401 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.24 mg/kg)
Number of subjects: 20
Study 16508401 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (5 mg/kg)
Number of subjects: 20
Study 16508401 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 14720267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg once daily
Number of subjects: 23
Study 14720267 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray 220 microg once daily
Number of subjects: 23
Study 14720267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 14720267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (FPANS)
Number of subjects: 23
Study 14720267 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA) aqueous nasal spray
Number of subjects: 23
Study 10675426 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamic stimulation
Number of subjects: 68
Study 10675426 — intervention group
Group type: COMPARATOR
Intervention: Thalamotomy
Number of subjects: 68
Study 9313671 — intervention group
Group type: EXPERIMENTAL
Intervention: Spermatic-cord block (10 mL of 0.5% plain bupivacaine)
Number of subjects: 48
Study 9313671 — intervention group
Group type: COMPARATOR
Intervention: Conventional analgesic regimen (general anaesthesia, fentanyl, and diclofenac)
Number of subjects: 48
Study 8370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (10 mg) administered 60 minutes prior to GHRH (100 micrograms i.v. bolus)
Number of subjects: 32
Study 8370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (10 mg) administered 60 minutes prior to a submaximal dose (3 micrograms i.v. bolus) of GHRH
Number of subjects: 32
Study 8370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pyridostigmine (120 mg)
Number of subjects: 32
Study 8370132 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of melatonin (10 mg) and pyridostigmine (120 mg)
Number of subjects: 32
Study 8370132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3011310 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nedocromil sodium
Number of subjects: 10
Study 3011310 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg nedocromil sodium
Number of subjects: 10
Study 3011310 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg nedocromil sodium
Number of subjects: 10
Study 3011310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31951148 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized controlling method (S-K)
Number of subjects: 60
Study 31951148 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited controlling method (L-K)
Number of subjects: 60
Study 31951148 — intervention group
Group type: COMPARATOR
Intervention: Tell-Show-Do Method (TSDM)
Number of subjects: 60
Study 29722640 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Number of subjects: 30
Study 29722640 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 26821260 — intervention group
Group type: EXPERIMENTAL
Intervention: Group physiotherapy
Number of subjects: 12
Study 23942245 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 459
Study 23942245 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 459
Study 23942245 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/MPA 1.5 mg
Number of subjects: 459
Study 23942245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 459
Study 21948807 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain packaging
Number of subjects: 52
Study 21948807 — intervention group
Group type: COMPARATOR
Intervention: Coloured packaging
Number of subjects: 52
Study 20304566 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 Gy
Number of subjects: 73
Study 20304566 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Gy
Number of subjects: 73
Study 20304566 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 Gy
Number of subjects: 73
Study 20304566 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all doses)
Number of subjects: 73
Study 20304566 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 25 Gy and lower doses (20 Gy and 15 Gy)
Number of subjects: 73
Study 19102184 — intervention group
Group type: EXPERIMENTAL
Intervention: T shape approach (Group B)
Number of subjects: 113
Study 19102184 — intervention group
Group type: COMPARATOR
Intervention: Traditional exposure approach (Group A)
Number of subjects: 113
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (n=28)
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy (n=30)
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (n=27)
Number of subjects: 115
Study 15647648 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole and placebo (n=30)
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients using NSAIDs or ASA
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients using NSAIDs or ASA
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive patients
Number of subjects: 115
Study 15647648 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative patients not using NSAIDs or ASA
Number of subjects: 115
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Directive parent education and behavior modification techniques
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Delorazepam (chlordesmethyldiazepam)
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaprazine
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Alimemazine (trimeprazine)
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting benzodiazepines
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer hypnotics
Number of subjects: 0
Study 12038875 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy or medical management
Number of subjects: 0
Study 9485131 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled‐onset extended release (COER) verapamil
Number of subjects: 557
Study 9485131 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine gastrointestinal therapeutic system (GITS)
Number of subjects: 557
Study 9485131 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine GITS
Number of subjects: 557
Study 9485131 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 557
Study 7666101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily on days 2 and 3 and placebo on days 4 to 6
Number of subjects: 538
Study 7666101 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg twice daily on days 2 to 6
Number of subjects: 538
Study 7666101 — intervention group
Group type: COMPARATOR
Intervention: Placebo on days 2 to 6
Number of subjects: 538
Study 2787477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy for ALL
Number of subjects: 733
Study 2787477 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell immunophenotype
Number of subjects: 733
Study 2787477 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytogenetic studies
Number of subjects: 733
Study 1131555 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour therapy conducted by medical students
Number of subjects: 12
Study 31846980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS (20 daily 40-min sessions, 77.5-Hz, 15-mA)
Number of subjects: 62
Study 31846980 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tACS
Number of subjects: 62
Study 31846980 — intervention group
Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 62
Study 30095983 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized clinical decision-support systems (CCDSS) after computer-based simulation (CBS) training
Number of subjects: 1051
Study 30095983 — intervention group
Group type: COMPARATOR
Intervention: No further intervention (comparison arm)
Number of subjects: 1051
Study 28587498 — intervention group
Group type: EXPERIMENTAL
Intervention: 2mA cathodal tDCS for 10 minutes
Number of subjects: 6
Study 28587498 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS for 10 minutes
Number of subjects: 6
Study 25280931 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation (MAN)
Number of subjects: 27
Study 25280931 — intervention group
Group type: COMPARATOR
Intervention: Stretching of the Lumbar spine (STR)
Number of subjects: 27
Study 25280931 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation (SHA)
Number of subjects: 27
Study 23743976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 110 mg BID (DE 110)
Number of subjects: 18113
Study 23743976 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg BID (DE 150)
Number of subjects: 18113
Study 23743976 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18113
Study 21393113 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing synbiotics (Bifidobacterium longum, Lactobacillus rhamonosus, prebiotics) and LCPUFA
Number of subjects: 393
Study 21393113 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 393
Study 21393113 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk containing synbiotics
Number of subjects: 393
Study 19057983 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT with 60 mg/kg and red laser light (1,000 J/cm)
Number of subjects: 48
Study 19057983 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT with 30 mg/kg
Number of subjects: 48
Study 19057983 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT with 60 mg/kg and red laser light
Number of subjects: 48
Study 16541846 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (14 subjects) wearing test shoes with insoles that stimulated the plantar surfaces
Number of subjects: 24
Study 16541846 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects) wearing placebo shoes
Number of subjects: 24
Study 14681639 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied frozen autologous platelets (FAP)
Number of subjects: 15
Study 14681639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 15
Study 16634116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 5 microg b.i.d.
Number of subjects: 222
Study 16634116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10 microg b.i.d.
Number of subjects: 222
Study 16634116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (both dosages)
Number of subjects: 222
Study 10504642 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal aortic arch cannulation
Number of subjects: 34
Study 10504642 — intervention group
Group type: COMPARATOR
Intervention: Conventional cannulation of the ascending aorta (control group)
Number of subjects: 34
Study 8684757 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate feeding
Number of subjects: 0
Study 8684757 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (control)
Number of subjects: 0
Study 1649790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 20 days (group A)
Number of subjects: 312
Study 1649790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 30 days (group B)
Number of subjects: 312
Study 1649790 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate for 40 days (group C)
Number of subjects: 312
Study 6401612 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2-rebreathing indirect Fick method
Number of subjects: 15
Study 29199652 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (6 fractions per week, 2 Gy per fraction)
Number of subjects: 60
Study 29199652 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation (5 fractions per week, 2 Gy per fraction)
Number of subjects: 60
Study 27654449 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 101
Study 27654449 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study 24718066 — intervention group
Group type: EXPERIMENTAL
Intervention: Kineflex-L Disc (investigational group)
Number of subjects: 457
Study 24718066 — intervention group
Group type: COMPARATOR
Intervention: CHARITE artificial disc (control group)
Number of subjects: 457
Study 22406657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 121
Study 22406657 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine with phenytoin
Number of subjects: 121
Study 20663737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-NOx unflued gas heaters
Number of subjects: 400
Study 17209164 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiscal and intraforaminal injections of a steroid, an anesthetic, and O(2)-O(3) mixture (group B)
Number of subjects: 159
Study 17209164 — intervention group
Group type: COMPARATOR
Intervention: Intradiscal and intraforaminal injections of a steroid and an anesthetic (group A)
Number of subjects: 159
Study 15623834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Number of subjects: 54
Study 15623834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate
Number of subjects: 54
Study 15623834 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced iron + Na(2)EDTA
Number of subjects: 54
Study 15623834 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate and reduced iron + Na(2)EDTA
Number of subjects: 54
Study 12218523 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.8‐2.5 vol%)
Number of subjects: 116
Study 12218523 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.5‐1.4 vol%)
Number of subjects: 116
Study 10335537 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with birthweight < 2500 g
Number of subjects: 861
Study 7656629 — intervention group
Group type: EXPERIMENTAL
Intervention: Local radiotherapy (7 Gy, three daily sessions, 10 to 15 days after thoracoscopy)
Number of subjects: 40
Study 7656629 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy (control group)
Number of subjects: 40
Study 2789920 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 30 mg single dose on day 1 (group A, n = 9)
Number of subjects: 27
Study 2789920 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 30 mg two consecutive doses on days 1 and 2 (group B, n = 9)
Number of subjects: 27
Study 2789920 — intervention group
Group type: EXPERIMENTAL
Intervention: APD 60 mg single dose on day 1 (group C, n = 9)
Number of subjects: 27
Study 31785624 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term nutritional supplementation (greater energy content diet)
Number of subjects: 18
Study 28634280 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical clipping
Number of subjects: 134
Study 28634280 — intervention group
Group type: COMPARATOR
Intervention: Endovascular coiling
Number of subjects: 134
Study 27471018 — intervention group
Group type: EXPERIMENTAL
Intervention: S4HM intervention (interactive seminar, eHealth messaging, behavioral contract, parental newsletters)
Number of subjects: 322
Study 27471018 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 322
Study 27471018 — intervention group
Group type: EXPERIMENTAL
Intervention: S4HM intervention
Number of subjects: 322
Study 23793945 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide (10 mg/h)
Number of subjects: 109
Study 23793945 — intervention group
Group type: COMPARATOR
Intervention: Bolus of furosemide (20 mg/6 h)
Number of subjects: 109
Study 23793945 — intervention group
Group type: COMPARATOR
Intervention: Bolus of furosemide (20 mg/8 h)
Number of subjects: 109
Study 23951788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozicure Oxygen Activator
Number of subjects: 99
Study 23951788 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Quick
Number of subjects: 99
Study 23951788 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 99
Study 21494186 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk administered 3 times daily for 8 weeks
Number of subjects: 74
Study 21494186 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 3 times daily for 8 weeks
Number of subjects: 74
Study 17665424 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 200
Study 17665424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17665424 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Infliximab
Number of subjects: 200